SECURITIES AND EXCHANGE COMMISSION

Issuer Delisting; Notice of Application of Applera Corporation to Withdraw its Applera
Corporation-Applied Biosystems Group common stock $.01 par value, together with rights to
purchase series A participating junior preferred stock, $.01 par value, and Applera Corporation-
Celera Genomics Group common stock, $.01 par value, together with rights to purchase series
B participating junior preferred stock, $.01 par value, from Listing and Registration on the
Pacific Exchange, Inc. File No. 1-04389

December 1, 2005

On November 14, 2005, Applera Corporation, a Delaware corporation ("Issuer"), filed

an application with the Securities and Exchange Commission ("Commission"), pursuant to

Section 12(d) of the Securities Exchange Act of 1934 ("Act")[1] and Rule 12d2-2(d) thereunder,[2]

to withdraw its Applera Corporation-Applied Biosystems Group common stock $.01 par value,

together with rights to purchase series A participating junior preferred stock, $.01 par value,

and Applera Corporation-Celera Genomics Group common stock, $.01 par value, together with

rights to purchase series B participating junior preferred stock, $.01 par value (collectively

"Securities"), from listing and registration on the Pacific Exchange, Inc. ("PCX").

The Board of Directors ("Board") of the Issuer approved a resolution on June 16, 2005

to withdraw the Securities from PCX. The Issuer stated that the Board determined that it is in

the best interest of the Issuer and its stockholders to withdraw the Securities from PCX to avoid

the direct and indirect costs associated with the listing of the Securities on PCX since the

Securities are listed and traded on the New York Stock Exchange, Inc. ("NYSE").

The Issuer stated in its application that it has complied with applicable rules of PCX by

providing PCX with the required documents governing the withdrawal of securities from listing

and registration on PCX. The Issuer's application relates solely to the withdrawal of the

---

[1]   15 U.S.C. 78l(d).

Securities from listing on PCX and shall not affect its continued listing on NYSE or its

obligation to be registered under Section 12(b) of the Act.[3]

Any interested person may, on or before December 23, 2005, comment on the facts

bearing upon whether the application has been made in accordance with the rules of PCX, and

what terms, if any, should be imposed by the Commission for the protection of investors. All

comment letters may be submitted by either of the following methods:

Electronic comments:

- Send an e-mail to rule-comments@sec.gov. Please include the File Number 1-04389

  or;

Paper comments:

- Send paper comments in triplicate to Jonathan G. Katz, Secretary, Securities and

Exchange Commission, 100 F Street, NE,Washington, DC 20549-9303.

All submissions should refer to File Number 1-04389. This file number should be included on

the subject line if e-mail is used. To help us process and review your comments more

efficiently, please use only one method. The Commission will post all comments on the

Commission's Internet Web site (http://www.sec.gov/rules/delist.shtml). Comments are also

available for public inspection and copying in the Commission's Public Reference Room. All

comments received will be posted without change; we do not edit personal identifying

information from submissions. You should submit only information that you wish to make

available publicly.

---

[2]   17 CFR 240.12d2-2(d).
[3]   15 U.S.C. 78l(b).

The Commission, based on the information submitted to it, will issue an order granting the application after the date mentioned above, unless the Commission determines to order a hearing on the matter.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority. [4]

Jonathan G. Katz
Secretary

---

[4]   17 CFR 200.30-3(a)(1).